Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07624396 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Association Between Circulating BDNF Levels and Cardioembolic Strokes in Patients Treated for Ischemic Stroke

Study acronym: METAPROFIL 1
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 2 months later Jun 2031 → Sep 2031
See other at-risk trials from Centre Hospitalier Universitaire Dijon

Record History

  1. Recruitment opened Primary endpoints: details revised at 1 of 1 entry · Primary and study completion pushed from Jun 2031 to Sep 2031 · Start date changed from estimate of Jun 2026 to Sep 23, 2026 · 2 more Show 5 more changesShow less
    • Primary endpoints: details revised at 1 of 1 entry
    • Primary and study completion pushed from Jun 2031 to Sep 2031
    • Start date changed from estimate of Jun 2026 to Sep 23, 2026
    • Eligibility criteria expanded, about 9 words
    • Site details revised
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Atrial fibrillation (AF) is associated with serious complications, including embolic strokes, heart failure, and mortality. Disruption of normal blood flow in the atrium, particularly in the context of an endocardium predisposed to thrombosis, increases the risk of thrombus formation. Once dislodged from the atrial cavity and traveling to the cerebral arteries, these thrombi can cause a cardioembolic stroke. The main risk factors for atrial cardiomyopathy (ACM) and AF are metabolic syndrome and aging. ACM is a condition that is difficult to diagnose because it is not clearly defined, except through histological analysis. Guided by the results of our experimental approaches, the investigators aim to address this challenge by examining ACM through the lens of one of its complications: cardioembolic stroke. BDNF (Brain-Derived Neurotrophic Factor) is a neurotrophic factor involved in inflammatory and metabolic processes that may play a key role in the development of these complications. This study explores the association between circulating levels of BDNF and the morphological and metabolic characteristics of ACM, as assessed by cardiac and brain imaging studies
Trial Details
NCT Number NCT07624396
Lead Sponsor Centre Hospitalier Universitaire Dijon
Conditions Acute Ischemic Stroke
Enrollment 150 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov